As part of our mission to improve the care and survival of patients with Castleman disease, the CDCN aims to support and educate the community about Castleman disease clinical trials as well as facilitate the research that forms the basis for clinical trials.
There are currently two open clinical trials, one in the United States and one in China.
This is the first USA clinical trial for a new Castleman disease treatment since 2012 is now open! The University of Pennsylvania and the University of Arkansas for Medical Sciences launched a clinical trial to evaluate the medication sirolimus. The trial is open for idiopathic multicentric Castleman disease patients that did not sufficiently get better with, or relapsed on, anti-IL6 treatment (siltuximab or tocilizumab). The trial has been posted to the federal registry for all clinical trials and more information can be found here. Please email CDtrial@pennmedicine.upenn.edu for more information.
The Peking Union Medical College Hospital in Beijing, China is currently recruiting for a clinical trial that is exploring the effectiveness and safety of the medications bortezomib, cyclophosphamide and dexamethasone (BCD regimen). The trial is open for patients who are newly diagnosed idiopathic multicentric Castleman disease. More information about this trial can be found here.